Technology
Health
Biotechnology

Atara Biotherapeutics

$23.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.28 (-1.19%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ATRA and other stocks, options, ETFs, and crypto commission-free!

About

Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. Read More The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Employees
311
Headquarters
South San Francisco, California
Founded
2012
Market Cap
1.07B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
556.90K
High Today
$24.32
Low Today
$22.75
Open Price
$23.66
Volume
181.62K
52 Week High
$51.40
52 Week Low
$22.05

Collections

Technology
Health
Biotechnology
Medical
Therapy
2014 IPO
US
North America

News

Seeking AlphaMay 13

Atara Biotherapeutics: T-Cell Therapy Developer With Late-Stage Candidate In Rare Disease

Atara Biotherapeutics (ATRA) is an allogenic, off-the-shelf T-cell therapy developer with a late-stage pipeline targeting post-transplant lymphoproliferative disorder (EBV+PTLD) associated with Epstein-Barr Virus as its lead indication, with a slew of further indications backing it up.

201
NasdaqMay 9

Notable Thursday Option Activity: OXY, ATRA, SPWR

102
Yahoo FinanceMay 9

Atara Biotherapeutics: 1Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $66.3 million in its first quarter. The South San Francisco, California-based company said it had a loss of $1.44 per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.48 per share. Atara Biotherapeutics shares have decreased slightly more than 1% since the beginning of the year. The stock has declined 13%...

26

Earnings

-$1.75
-$1.47
-$1.20
-$0.92
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 31, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.